BACKGROUND: Guidelines from the United Kingdom and the United States on risk stratification after polypectomy differ, as do recommended surveillance intervals. OBJECTIVE: To compare risk for advanced colorectal neoplasia at 1-year colonoscopy among patients cross-classified by U.S. and U.K. surveillance guidelines. DESIGN: Pooled analysis of 4 prospective studies between 1984 and 1998. SETTING: Academic and private clinics in the United States. PATIENTS: 3226 postpolypectomy patients with 6- to 18-month follow-up colonoscopy. MEASUREMENTS: Rates of advanced neoplasia (an adenoma ≥1 cm, high-grade dysplasia, >25% villous architecture, or invasive cancer) at 1 year, compared across U.S. and U.K. risk categories. RESULTS: Advanced neoplasia was detected 1 year after polypectomy in 3.8% (95% CI, 2.7% to 4.9%) of lower-risk patients and 11.2% (CI, 9.8% to 12.6%) of higher-risk patients by U.S. criteria. According to U.K. criteria, 4.4% (CI, 3.3% to 5.4%) of low-risk patients, 9.9% (CI, 8.3% to 11.5%) of intermediate-risk patients, and 18.7% (CI, 14.8% to 22.5%) of high-risk patients presented with advanced neoplasia; U.K. high-risk patients comprised 12.1% of all patients. All U.S. lower-risk patients were low-risk by U.K. criteria; however, more patients were classified as low-risk, because the U.K. guidelines do not consider histologic features. Higher-risk U.S. patients were distributed across the 3 U.K. categories. Among all patients with advanced neoplasia, 26.3% were reclassified by the U.K. criteria to a higher-risk category and 7.0% to a lower-risk category, with a net 19.0% benefiting from detection 2 years earlier. Overall, substitution of U.K. for U.S. guidelines resulted in an estimated 0.03 additional colonoscopy every 5 years per patient. LIMITATIONS: Patients were enrolled 15 to 20 years ago, and quality measures for colonoscopy were unavailable. Patients lacking follow-up colonoscopy or with surveillance colonoscopy after 6 to 18 months and those with cancer or insufficient baseline adenoma characteristics were excluded (2076 of 5302). CONCLUSION: Application of the U.K. guidelines in the United States could identify a subset of high-risk patients who may warrant a 1-year clearing colonoscopy without substantially increasing rates of colonoscopy. PRIMARY FUNDING SOURCE: European Union Public Health Programme.
BACKGROUND: Guidelines from the United Kingdom and the United States on risk stratification after polypectomy differ, as do recommended surveillance intervals. OBJECTIVE: To compare risk for advanced colorectal neoplasia at 1-year colonoscopy among patients cross-classified by U.S. and U.K. surveillance guidelines. DESIGN: Pooled analysis of 4 prospective studies between 1984 and 1998. SETTING: Academic and private clinics in the United States. PATIENTS: 3226 postpolypectomy patients with 6- to 18-month follow-up colonoscopy. MEASUREMENTS: Rates of advanced neoplasia (an adenoma ≥1 cm, high-grade dysplasia, >25% villous architecture, or invasive cancer) at 1 year, compared across U.S. and U.K. risk categories. RESULTS:Advanced neoplasia was detected 1 year after polypectomy in 3.8% (95% CI, 2.7% to 4.9%) of lower-risk patients and 11.2% (CI, 9.8% to 12.6%) of higher-risk patients by U.S. criteria. According to U.K. criteria, 4.4% (CI, 3.3% to 5.4%) of low-risk patients, 9.9% (CI, 8.3% to 11.5%) of intermediate-risk patients, and 18.7% (CI, 14.8% to 22.5%) of high-risk patients presented with advanced neoplasia; U.K. high-risk patients comprised 12.1% of all patients. All U.S. lower-risk patients were low-risk by U.K. criteria; however, more patients were classified as low-risk, because the U.K. guidelines do not consider histologic features. Higher-risk U.S. patients were distributed across the 3 U.K. categories. Among all patients with advanced neoplasia, 26.3% were reclassified by the U.K. criteria to a higher-risk category and 7.0% to a lower-risk category, with a net 19.0% benefiting from detection 2 years earlier. Overall, substitution of U.K. for U.S. guidelines resulted in an estimated 0.03 additional colonoscopy every 5 years per patient. LIMITATIONS: Patients were enrolled 15 to 20 years ago, and quality measures for colonoscopy were unavailable. Patients lacking follow-up colonoscopy or with surveillance colonoscopy after 6 to 18 months and those with cancer or insufficient baseline adenoma characteristics were excluded (2076 of 5302). CONCLUSION: Application of the U.K. guidelines in the United States could identify a subset of high-risk patients who may warrant a 1-year clearing colonoscopy without substantially increasing rates of colonoscopy. PRIMARY FUNDING SOURCE: European Union Public Health Programme.
Authors: David A Lieberman; Douglas K Rex; Sidney J Winawer; Francis M Giardiello; David A Johnson; Theodore R Levin Journal: Gastroenterology Date: 2012-07-03 Impact factor: 22.682
Authors: Stuart R Cairns; John H Scholefield; Robert J Steele; Malcolm G Dunlop; Huw J W Thomas; Gareth D Evans; Jayne A Eaden; Matthew D Rutter; Wendy P Atkin; Brian P Saunders; Anneke Lucassen; Paul Jenkins; Peter D Fairclough; Christopher R J Woodhouse Journal: Gut Date: 2010-05 Impact factor: 23.059
Authors: Douglas K Rex; M Brian Fennerty; Prateek Sharma; Tonya Kaltenbach; Roy Soetikno Journal: Gastrointest Endosc Date: 2009-11-17 Impact factor: 9.427
Authors: Charles J Kahi; David G Hewett; Dustin Lee Norton; George J Eckert; Douglas K Rex Journal: Clin Gastroenterol Hepatol Date: 2010-10-01 Impact factor: 11.382
Authors: Vikram Boolchand; Gregory Olds; Joseph Singh; Pankaj Singh; Amitabh Chak; Gregory S Cooper Journal: Ann Intern Med Date: 2006-11-07 Impact factor: 25.391
Authors: J A Baron; M Beach; J S Mandel; R U van Stolk; R W Haile; R S Sandler; R Rothstein; R W Summers; D C Snover; G J Beck; J H Bond; E R Greenberg Journal: N Engl J Med Date: 1999-01-14 Impact factor: 91.245
Authors: Ethna McFerran; James F O'Mahony; Richard Fallis; Duncan McVicar; Ann G Zauber; Frank Kee Journal: Epidemiol Rev Date: 2017-01-01 Impact factor: 6.222
Authors: Reinier G S Meester; Iris Lansdorp-Vogelaar; Sidney J Winawer; Ann G Zauber; Amy B Knudsen; Uri Ladabaum Journal: Ann Intern Med Date: 2019-09-24 Impact factor: 25.391
Authors: Ernst J Kuipers; William M Grady; David Lieberman; Thomas Seufferlein; Joseph J Sung; Petra G Boelens; Cornelis J H van de Velde; Toshiaki Watanabe Journal: Nat Rev Dis Primers Date: 2015-11-05 Impact factor: 52.329
Authors: Matthew D Rutter; James East; Colin J Rees; Neil Cripps; James Docherty; Sunil Dolwani; Philip V Kaye; Kevin J Monahan; Marco R Novelli; Andrew Plumb; Brian P Saunders; Siwan Thomas-Gibson; Damian J M Tolan; Sophie Whyte; Stewart Bonnington; Alison Scope; Ruth Wong; Barbara Hibbert; John Marsh; Billie Moores; Amanda Cross; Linda Sharp Journal: Gut Date: 2019-11-27 Impact factor: 31.793
Authors: Wendy Atkin; Kate Wooldrage; Amy Brenner; Jessica Martin; Urvi Shah; Sajith Perera; Fiona Lucas; Jeremy P Brown; Ines Kralj-Hans; Paul Greliak; Kevin Pack; Jill Wood; Ann Thomson; Andrew Veitch; Stephen W Duffy; Amanda J Cross Journal: Lancet Oncol Date: 2017-04-28 Impact factor: 41.316